Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | AGXT | P21549 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049247 | 0.89 | LOXL2 (0.56) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL2090531 | 0.87 | LOXL2 (0.55) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL2088773 | 0.85 | LOXL2 (0.53) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL291730 | 0.83 | LOXL2 (0.64) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL2249038 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL9037490 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL6013090 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL4049122 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL6243293 | 0.80 | LOXL2 (0.66) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL140395 | 0.80 | LOXL2 (0.71) | LOXL2AGXTHTR2BHTR1ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149990-A1 | NIRMATRELVIR ANALOGS AS 3C LIKE PROTEASE INHIBITORS FOR TREATING VIRAL INFECTIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-4377300-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | The University of Manchester (GB) | 2024-06-05 | — | — | EP | disclosed |
| EP-3253737-B3 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| EP-4347563-A1 | 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117730077-A | 6-substituted naphthalene-1, 3-disulfonic acid derivatives as modulators of extracellular nicotinamide ribophosphate transferase (ENAMPT) for the treatment of, for example, diabetes | 曼彻斯特大学 | 2024-03-19 | — | — | CN | disclosed |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-14 | — | — | US | disclosed |
| WO-2024052698-A1 | COMPOSITIONS OF COPPER COMPLEXES | UNIVERSITY OF CENTRAL LANCASHIRE (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
| EP-0903349-A2 | CCR-3 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-24 | — | — | EP | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000403-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5606078-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0678514-A1 | 3,5-Disubstituted tetrahydrofuran-2-ones | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | LOXL2 1259/4885AGXT 4182/4885HTR2B 129/4885 |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | LOXL2 4146/4885AGXT 3374/4885HTR2B 135/4885 |
| US-20240132504-A1 | Compounds Useful as RET Inhibitors | RET, BCR, REL | LOXL2 1512/4885AGXT 3007/4885HTR2B 2862/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | LOXL2 1821/4885AGXT 2473/4885HTR2B 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.